Dexcom ( (DXCM) ) has released its Q1 earnings. Here is a breakdown of the information Dexcom presented to its investors.
Dexcom, Inc., a leader in glucose biosensing technology, has reported its financial results for the first quarter of 2025, showcasing its continued growth and strategic advancements in the healthcare technology sector. The company, known for its innovative diabetes management solutions, remains at the forefront of the industry with its cutting-edge products.
In the first quarter of 2025, Dexcom achieved a 12% increase in revenue year-over-year, reaching $1.036 billion. This growth was driven by a 15% rise in U.S. revenue and a 7% increase in international revenue. The company also reported a GAAP operating income of $133.7 million, marking a significant improvement from the previous year. Additionally, Dexcom announced a $750 million share repurchase program, reflecting confidence in its financial stability and future prospects.
Key highlights from the quarter include the expansion of coverage for Dexcom’s Continuous Glucose Monitoring (CGM) systems in the U.S., with two of the three largest Pharmacy Benefit Managers now covering the product for all diabetes patients. The company also expanded its distribution footprint by launching Stelo on Amazon and received FDA clearance for the Dexcom G7 15 Day System shortly after the quarter ended.
Looking ahead, Dexcom has updated its fiscal year 2025 guidance, maintaining its revenue growth target of 14% and adjusting its Non-GAAP Gross Profit Margin to approximately 62% due to near-term supply dynamics. The company remains focused on advancing its product portfolio and expanding global access to its glucose biosensors, positioning itself for continued success in the healthcare technology market.